These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 26617778)

  • 1. Thymidine phosphorylase and hypoxia-inducible factor 1-α expression in clinical stage II/III rectal cancer: association with response to neoadjuvant chemoradiation therapy and prognosis.
    Lin S; Lai H; Qin Y; Chen J; Lin Y
    Int J Clin Exp Pathol; 2015; 8(9):10680-8. PubMed ID: 26617778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
    Liersch T; Langer C; Ghadimi BM; Kulle B; Aust DE; Baretton GB; Schwabe W; Häusler P; Becker H; Jakob C
    J Clin Oncol; 2006 Sep; 24(25):4062-8. PubMed ID: 16943523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
    Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C).
    Dewdney A; Cunningham D; Tabernero J; Capdevila J; Glimelius B; Cervantes A; Tait D; Brown G; Wotherspoon A; Gonzalez de Castro D; Chua YJ; Wong R; Barbachano Y; Oates J; Chau I
    J Clin Oncol; 2012 May; 30(14):1620-7. PubMed ID: 22473163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical analysis of thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer (cUICC II/III): correlation with histopathologic tumor regression after 5-fluorouracil-based long-term neoadjuvant chemoradiotherapy.
    Jakob C; Liersch T; Meyer W; Baretton GB; Häusler P; Schwabe W; Becker H; Aust DE
    Am J Surg Pathol; 2005 Oct; 29(10):1304-9. PubMed ID: 16160472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pretreatment Tumor Thickness as a Predictor of Pathologic Complete Response to Neoadjuvant Chemoradiation Therapy for Stage II/III Rectal Adenocarcinoma.
    Xu B; Chen Y; Guo Y; Zhou D; Yue Z; Duan Q; Yang Y; Guan G; Chi P; Lin C
    Am J Clin Oncol; 2018 Jun; 41(6):601-606. PubMed ID: 27672742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Significance of C-Reactive Protein-to-Albumin Ratio with Rectal Cancer Patient Undergoing Chemoradiotherapy Followed by Surgery.
    Ide S; Toiyama Y; Okugawa Y; Oki S; Yasuda H; Fujikawa H; Yoshiyama S; Hiro J; Kobayashi M; Ohi M; Araki T; Kusunoki M
    Anticancer Res; 2017 Oct; 37(10):5797-5804. PubMed ID: 28982904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant treatment for resected rectal cancer: impact of standard and intensified postoperative chemotherapy on disease-free survival in patients undergoing preoperative chemoradiation-a propensity score-matched analysis of an observational database.
    Garlipp B; Ptok H; Benedix F; Otto R; Popp F; Ridwelski K; Gastinger I; Benckert C; Lippert H; Bruns C
    Langenbecks Arch Surg; 2016 Dec; 401(8):1179-1190. PubMed ID: 27830368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Critical role of bevacizumab scheduling in combination with pre-surgical chemo-radiotherapy in MRI-defined high-risk locally advanced rectal cancer: Results of the BRANCH trial.
    Avallone A; Pecori B; Bianco F; Aloj L; Tatangelo F; Romano C; Granata V; Marone P; Leone A; Botti G; Petrillo A; Caracò C; Iaffaioli VR; Muto P; Romano G; Comella P; Budillon A; Delrio P
    Oncotarget; 2015 Oct; 6(30):30394-407. PubMed ID: 26320185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypoxia-related proteins in patients with rectal cancer undergoing neoadjuvant combined modality therapy.
    Lee-Kong SA; Ruby JA; Chessin DB; Pucciarelli S; Shia J; Riedel ER; Nitti D; Guillem JG
    Dis Colon Rectum; 2012 Sep; 55(9):990-5. PubMed ID: 22874607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival analysis in rectal carcinoma after neoadjuvant chemoradiation: various methods with different results.
    Merkel S; Weber K; Göhl J; Agaimy A; Fietkau R; Hohenberger W; Grützmann R; Hermanek P
    Int J Colorectal Dis; 2017 Sep; 32(9):1295-1301. PubMed ID: 28730369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management.
    Smith JJ; Chow OS; Gollub MJ; Nash GM; Temple LK; Weiser MR; Guillem JG; Paty PB; Avila K; Garcia-Aguilar J;
    BMC Cancer; 2015 Oct; 15():767. PubMed ID: 26497495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes of elderly patients receiving neoadjuvant chemoradiation for locally advanced rectal cancer.
    Jiang DM; Raissouni S; Mercer J; Kumar A; Goodwin R; Heng DY; Tang PA; Doll C; MacLean A; Powell E; Price-Hiller J; Monzon J; Cheung WY; Vickers MM
    Ann Oncol; 2015 Oct; 26(10):2102-6. PubMed ID: 26232491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of histologic tumor regression, thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer UICC Stage II/III after neoadjuvant chemoradiotherapy.
    Jakob C; Liersch T; Meyer W; Baretton GB; Schwabe W; Häusler P; Kulle B; Becker H; Aust DE
    Am J Surg Pathol; 2006 Sep; 30(9):1169-74. PubMed ID: 16931962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53.
    Chiorean EG; Sanghani S; Schiel MA; Yu M; Burns M; Tong Y; Hinkle DT; Coleman N; Robb B; LeBlanc J; Clark R; Bufill J; Curie C; Loehrer PJ; Cardenes H
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):25-32. PubMed ID: 22610353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer.
    Chau I; Brown G; Cunningham D; Tait D; Wotherspoon A; Norman AR; Tebbutt N; Hill M; Ross PJ; Massey A; Oates J
    J Clin Oncol; 2006 Feb; 24(4):668-74. PubMed ID: 16446339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of clinical and pathological stages on locally advanced rectal carcinoma after neoadjuvant chemoradiotherapy.
    Wen B; Zhang L; Wang C; Huang R; Peng H; Zhang T; Dong J; Xiao W; Zeng Z; Liu M; Gao Y
    Radiat Oncol; 2015 Jun; 10():124. PubMed ID: 26040453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant chemoradiation therapy using concurrent S-1 and irinotecan in rectal cancer: impact on long-term clinical outcomes and prognostic factors.
    Nakamura T; Yamashita K; Sato T; Ema A; Naito M; Watanabe M
    Int J Radiat Oncol Biol Phys; 2014 Jul; 89(3):547-55. PubMed ID: 24929164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5-FU-based neo-adjuvant chemoradiotherapy in rectal cancer.
    Jakob C; Aust DE; Meyer W; Baretton GB; Schwabe W; Häusler P; Becker H; Liersch T
    J Pathol; 2004 Dec; 204(5):562-8. PubMed ID: 15538739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computed tomography with histological correlation for evaluating tumor regression of rectal carcinoma after preoperative chemoradiation therapy.
    Lee CT; Chow NH; Liu YS; Lin SC; Lin PC; Wu YH; Lee JC; Tsai HM
    Hepatogastroenterology; 2012; 59(120):2484-9. PubMed ID: 22497951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.